Certain DNA biomarkers can actually predict survival for some patients with rare&nbsp;brain tumors. Research is underway at The James to understand the molecular landscape for brain tumor patients&mdash;particularly which markers predict patient survival outcomes as well as responses to specific therapies. In this study, experts are looking at MGMT, a gene known as a DNA repair protein. The study was the first of its kind to look at survival outcomes with MGMT and why it&rsquo;s important for certain brain tumors. It also marked the first time that MGMT promoter methylation&mdash;how the protein &ldquo;reads&rdquo;&mdash;was significantly associated with survival in certain brain tumor patients. This kind of precision medicine enables researchers to gather, study and use information to best inform clinical decision-making and treatments.